Richard Greenberg, MD

Connect

rngree01@uky.edu

Positions

  • Professor

College Unit(s)

Other Affiliation(s)
  • Internal Medicine - Infectious Disease

Biography and Education

Education

Fellowship - Louisiana State University Medical Center NIH Training Fellowship- University of Virginia Medical Center Internship & Residency - Indiana University Medical Center; Louisiana State University Medical School - Tuft University School of Medicine

Research

Clinical

Industrial Sponsored Vaccine trials: hepatitis A and B, HIV-1(Remune & Merck), Quilimmune-P vaccine for pneumoccocal pneumonia in the elderly,  Merck Varicella and zoster vaccines, DynPort CCSV-smallpox vaccine (for DoD), Vaxgen rPA, Acambis Acam 2000 and Acam 3000 (MVA), Vaxgen LC16M8c, DynPort Botulism and Plague Vaccines (DoD),  oral Cholera (PaxVax), oral H5 influenza vaccine (PaxVax), Clostridium difficile (Acambis), West Nile (Acambis) 13-valent pneumococcal vaccine (Wyeth),  MVA (Bavarian-Nordic), and subunit herpes zoster (GSK).

HIV clinical trials (Industry):  MDI-Pentamidine, Itraconazole for thrush, Delavirdine, Nevirapine, GM CSF, Abacavir, 935U83, DMP-266, Ritonavir, Saquinavir soft capsule formulation (Fortovase), once-a-day Didanosine, recombinant nerve growth factor, Indinavir studies, FTC, Remune vaccine, Maraviroc, Tenofovir, Capravirine, Tipranivir, Atazanavir, Tibotec TMC 125, TMC 114, VirXsys, and L-756423.

Subunit (sub-investigator) for Group Health Research Institute, Seattle, Washington, VTEU (funded by NIH-NIAID)

 

 

Selected Publications

Gurwith M, Lock M, Taylor EM, Ishioka G, Alexander J, Mayall T, Ervin JE, Greenberg RN, Strout C, Treanor JJ, Webby R, Wright PF. Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study. Lancet Infect Dis. 2013 Mar;13(3):238-50, 2013 Jan 28. pii: S1473-3099(12)70345-6. doi: 10.1016/S1473-3099(12)70345-6. McGarrity GJ, G Hoyah, A Winemille, K Andre, D Stein, G Blick, RN Greenberg, C Kinder, A Zolopa, G Binder-Scholl, P Tebas, CH. June, LM Humeau, T Rebello. Patient monitoring and follow-up in lentiviral clinical trials. J Gene Med. 2013 Feb;15(2):78-82. (Epub DOI: 10.1002/jgm.2691) Morrison VA, Oxman MN, Levin MJ, Schmader KE, Guatelli JC, Betts RF, Gelb LD, Pachucki CT, Keay SK, Menzies B, Griffin MR, Kaufman CA, Marques AR, Toney JF, Simberkoff MS, Serrao R, Arbeit RD, Gnann JW, Greenberg RN, Holodniy M, Keitel WA, Yeh SS, Davis LE, Crawford GE, Neuzil K, Johnson GR, Zhang JH, Harbecke R, Chan ISF, Keller PM, Williams HM, Boardman, KD , Silber JL, Annunziato PW for the Shingles Prevention Study Group.Safety of Zoster Vaccine in Elderly Adults Following Documented Herpes Zoster. J Infect Dis 2013 Aug 15;208(4):559-63 (doi: 10.1093/infdis/jit182 First published online: April 30, 2013). Jackson LA, A Gurtman, K Rice, K Pauksens, RN Greenberg, TR Jones, DA Scott, EA Emini, WC Gruber, B Schmoele-Thoma on behalf of the 3005 study group. Immunogenicity and Safety of a 13-valent Pneumococcal Conjugate Vaccine in Adults 70 Years of Age and Older Previously Vaccinated With 23-valent Pneumococcal Polysaccharide Vaccine. Vaccine 2013 Aug 2;31(35):3585-93 May 17. pii: S0264-410X(13)00588-4. doi: 10.1016/j.vaccine.2013.05.010. [Epub ahead of print] Myint T AM Anderson, A Sanchez, A Farabi, C Hage, JW Baddley, Malhar Jhaveri, RN Greenberg, DM Bamberger, M Rodgers, TN Crawford, LJ Wheat. Histoplasmosis in Patients with Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS): Multicenter Study of Outcomes and Factors Associated with Relapse. Medicine Medicine (Baltimore). 2014 Jan;93(1):11-8. doi: 10.1097/MD.0000000000000016 Myint T, MN Al-Hasan, JA Ribes, BS Murphy, RN Greenberg. Temporal trends, Clinical Characteristics and Outcome of Histoplasmosis in a Tertiary Care Center in Kentucky, 2000-2009. J Int Assoc Provid AIDS Care. 2013 Sep 12. [Epub ahead of print] Chen WH, RN Greenberg, MF Pasetti, S Livio, M Lock, M Gurwith, MM Levine. Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR prepared from new master and working cell banks. Clinical and Vaccine Immunology (in press 10/28/2013) 2013 Oct 30. [Epub ahead of print]